DiaMedica Therapeutics

DMAC60

Penny Stock

$4.13arrow_drop_down5.05%-$0.22

Penny Stock

DMAC60

$4.13

arrow_drop_down5.05%-$0.22

Penny Stock

Performance History

Key Stats
Open	$4.35
Prev. Close	$4.37
EPS	-0.51
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$185.95M
PE Ratio	-

	LOW	HIGH
Day Range	3.98	4.35
52 Week Range	1.93	4.95

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.51

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About DiaMedica Therapeutics (DMAC)

DiaMedica Therapeutics Inc. (DMAC) is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and kidney diseases. The company's lead product, DM199, is a recombinant form of the protein known as KLK1, which plays a key role in regulating blood flow and inflammation. DM199 has shown promise in preclinical and clinical studies for the treatment of acute ischemic stroke and chronic kidney disease.

One of the key advantages of DM199 is its ability to target multiple pathways that contribute to the development and progression of these diseases. In acute ischemic stroke, DM199 has been shown to improve blood flow to the brain, reduce inflammation, and protect against neuronal damage. In chronic kidney disease, DM199 has demonstrated the ability to improve renal function, reduce fibrosis, and decrease inflammation.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Dietrich John Pauls MBA
Headquarters: Minneapolis
Employees: 16
Exchange: NASDAQ

Keep an eye on DiaMedica Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is DiaMedica Therapeutics 's (DMAC) price per share?

The current price per share for DiaMedica Therapeutics (DMAC) is $4.13. The stock has seen a price change of -$0.22 recently, indicating a -5.06% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for DiaMedica Therapeutics (DMAC)?

For DiaMedica Therapeutics (DMAC), the 52-week high is $4.95, which is 19.85% from the current price. The 52-week low is $1.94, the current price is 113.08% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is DiaMedica Therapeutics (DMAC) a growth stock?

DiaMedica Therapeutics (DMAC) has shown an average price growth of 0.41% over the past three years. It has received a score of 30 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying DiaMedica Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is DiaMedica Therapeutics (DMAC) stock price performance year to date (YTD)?

As of the latest data, DiaMedica Therapeutics (DMAC) has a year-to-date price change of 45.94%. Over the past month, the stock has experienced a price change of 15.69%. Over the last three months, the change has been 72.8%. Over the past six months, the figure is 44.91%. Looking at a longer horizon, the five-year price change stands at 48.56%.

help

Is DiaMedica Therapeutics (DMAC) a profitable company?

DiaMedica Therapeutics (DMAC) has a net income of -$19.38M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$21.27M. Furthermore, the EBITDA is -$22.35M.

help

What is the market capitalization of DiaMedica Therapeutics (DMAC)?

DiaMedica Therapeutics (DMAC) has a market capitalization of $185.95M. The average daily trading volume is 89.9K, indicating the stock's liquidity and investor engagement.